InvestorsHub Logo
Followers 19
Posts 1896
Boards Moderated 0
Alias Born 02/10/2014

Re: None

Wednesday, 05/28/2014 11:51:48 AM

Wednesday, May 28, 2014 11:51:48 AM

Post# of 48316
The new Zacks article is a good one. Obviously, I think his valuation is a bit low but the author did admit that the wildcard is Big Pharma's involvement. He didn't cover really anything on Merkel Cell which I find interesting. However, at this point, any positive news is good news and this meets this criteria.

http://finance.yahoo.com/news/oncosec-schedule-advance-immunopusle-clinical-113500271.html